2024 Counter WMD Innovation Challenge Winners Announced!

• First place: Thylacine Biotherapeutics, Inc.
• Second place: Ceria Therapeutics
• Third place: Vaxess Technologies

Innovations were entered for a chance to pitch and win funding from a $50,000 award at TechConnect World, furnished by Advanced Technology International (ATI) and the Medical CBRN Defense Consortium (MCDC). Up to 25 finalists pitched on-stage before a panel of judges to include federal funders, consortium managers, investors, and private corporations as well as a broader audience of attendees from the conference.

Areas of Interest:

• PREVENTION: Vaccine manufacturing platforms, needle free delivery platforms, mRNA vaccines for biological threat agent diseases, vaccine encapsulation technologies, vaccine capability areas, accelerated antibodies prototype development, etc.
  
  
• TREATMENT: Reactivating and consolidated nerve agent treatment systems, small molecule therapeutics, therapeutics capability areas, gene-encoded MCM development and response platforms, etc.
  
  
• DIAGNOSTICS: CBRN medical decision systems and agent identification, opioid exposure diagnosis, microphysiological systems, advanced diagnostic capabilities, etc.

• Center for Applied NanoBioscience and Medicine (ANBM) at The University of Arizona
• Ceria Therapeutics
• DxLab, Inc.
• Linshom Medical
• PrecNA LLC
• Quanterix Corporation
• ReliOx Corporation

• SimWerx
• SingleTimeMicroneedles
• SPOC Proteomics
• SynerGene Therapeutics, Inc.
• Thylacine Biotherapeutics Inc
• University of Maryland
• Vaxess Technologies